Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Based on Medical Records in Spain That Looks at Diarrhoea Control in People With Pulmonary Fibrosis Who Are Taking Nintedanib
Sponsor: Boehringer Ingelheim
Summary
This is an observational, non-interventional, and prospective post authorization safety study (PASS) that will describe the real-world proportion of patients that achieve nintedanib-associated diarrhoea control after 12 weeks of follow-up, in hospital settings in Spain. It will include outpatients (i.e., those attending ambulatory visits) with interstitial lung diseases (IPF) and other progressive pulmonary fibrosis (PPF) treated with nintedanib (150 mg bid) and having a first episode of diarrhoea after nintedanib initiation.
Official title: Observational, Multicentre, Prospective, Real-world Post-authorization Safety Study Describing the Achievement of Nintedanib-associated DIArrhoea Control After 12 Weeks of Follow-up in Patients With Idiopathic puLmonary FIBrosis (IPF) and Progressive Pulmonary Fibrosis (Other Than IPF) in Spain: the DIALFIB Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
18
Start Date
2024-07-16
Completion Date
2025-04-29
Last Updated
2026-05-13
Healthy Volunteers
No
Conditions
Interventions
Nintedanib
Participants received 150 milligrams (mg) Nintedanib, twice daily.
Locations (8)
Hospital Clínic i Provincial de Barcelona
Barcelona, Spain
Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Hospital Universitario de Cruces
Bizkaia, Spain
Hospital Universitario Virgen de las Nieves
Granada, Spain
Hospital de La Princesa
Madrid, Spain
Hospital Clínico San Carlos
Madrid, Spain
Hospital Álvaro Cunqueiro
Pontevedra, Spain
Hospital Clínico Universitario de Valencia
Valencia, Spain